BioSpace News Archive

Zomedica Corp., a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, reported consolidated financial results for the three months ended March 31, 2022.

Eiger Biopharmaceuticals Inc. (“Eiger”, Nasdaq: EIGR) and AnGes Inc. (“AnGes”, TYO: 4563) today announced that the companies entered into an agreement for the regulatory approval, marketing, and distribution of Zokinvy® (lonafarnib) for the treatment of Hutchinson-Gilford progeria syndrome (HGPS or progeria) and processing-deficient progeroid laminopathies (PL) in Japan.

Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced the grant of inducement awards to 15 new employees.

SQZ Biotechnologies Reports First Quarter 2022 Financial Results and Recent Portfolio Updates.

Psychemedics Corporation, the world’s largest provider of hair testing for drugs of abuse, announced financial results for the first quarter ended March 31, 2022, and the declaration of a cash dividend of $0.07 per share to be paid on June 24, 2022, to shareholders of record as of May 27, 2022.

Today, the U.S. Food and Drug Administration is providing an update on its work to increase the availability of infant and specialty formula products.

Tricida, Inc. announced financial results for the three months ended March 31, 2022 and provided an update on key initiatives.

MediWound Ltd. announced that the Company will release its financial results for the first quarter ended March 31, 2022 on Tuesday, May 17, 2022.

Xenon Pharmaceuticals Inc., a neurology-focused biopharmaceutical company, reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.

GBS Inc. announced its financial results for the third quarter ended March 31, 2022 and provided recent business updates.